Literature DB >> 26110520

SEQUENTIAL CENTRAL RETINAL VEIN AND OPHTHALMIC ARTERY OCCLUSIONS IN A PEDIATRIC CASE OF PRIMARY ANTIPHOSPHOLIPID SYNDROME.

Rony Gelman1, Stephen H Tsang.   

Abstract

PURPOSE: To report a case of sequential central retinal vein occlusion and ophthalmic artery occlusion in a patient with primary antiphospholipid syndrome.
METHODS: Observational case report. Color fundus photography, fluorescein angiography, and optical coherence tomography were used to document the progression of a central retinal vein occlusion and sequential development of an ophthalmic artery occlusion within a 1-week period in a patient with primary antiphospholipid syndrome.
RESULTS: A 15-year-old boy presented with unilateral blurry vision due to a central retinal vein occlusion along with other systemic symptoms. Within a 1-week period, he developed an ophthalmic artery occlusion in the same eye, with resulting bare light perception vision. Extensive evaluation by the pediatrics and rheumatology services led to a diagnosis of primary antiphospholipid syndrome as the etiology for the occlusions.
CONCLUSION: This case report illustrates the rapid sequential venous and arterial ocular thrombosis in a patient with primary antiphospholipid syndrome.

Entities:  

Mesh:

Year:  2016        PMID: 26110520      PMCID: PMC5511790          DOI: 10.1097/ICB.0000000000000161

Source DB:  PubMed          Journal:  Retin Cases Brief Rep        ISSN: 1935-1089


  10 in total

1.  Central retinal vein and ophthalmic artery occlusion in primary antiphospholipid syndrome.

Authors:  L Pek-Kiang Ang; A Tock-Han Lim; E-Y Yap
Journal:  Eye (Lond)       Date:  2004-04       Impact factor: 3.775

Review 2.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

3.  Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study.

Authors:  R Cobo-Soriano; S Sánchez-Ramón; M J Aparicio; M A Teijeiro; P Vidal; M Suárez-Leoz; M Rodriguez-Mahou; A Rodriguez-Huerta; E Fernández-Cruz; C Cortés
Journal:  Am J Ophthalmol       Date:  1999-12       Impact factor: 5.258

4.  Recurrent arterial thrombosis in a child: primary antiphospholipid antibody syndrome.

Authors:  Zümrüt Uysal; Figen Doğu; A Emin Kürekçi; Vildan Koşan Culha; Gülhis Deda; Mesiha Ekim; Nejat Akar; Mehmet Erterm; Aydan Ikincioğullari; Emel Babacan; Sevgi Gözdaşoğlu
Journal:  Pediatr Hematol Oncol       Date:  2002 Jan-Feb       Impact factor: 1.969

5.  Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis.

Authors:  D G Wahl; F Guillemin; E de Maistre; C Perret-Guillaume; T Lecompte; G Thibaut
Journal:  Lupus       Date:  1998       Impact factor: 2.911

Review 6.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

Review 7.  Primary anti-phospholipid antibody syndrome (APS): current concepts.

Authors:  Omar M Durrani; Caroline Gordon; Philip I Murray
Journal:  Surv Ophthalmol       Date:  2002 May-Jun       Impact factor: 6.048

8.  Antiphospholipid antibody syndrome in a six-year-old female patient.

Authors:  M Elizabeth Hartnett; Michael Laposata; Elizabeth Van Cott
Journal:  Am J Ophthalmol       Date:  2003-04       Impact factor: 5.258

9.  Primary antiphospholipid syndrome presenting with a branch retinal artery occlusion in a 15-year-old boy.

Authors:  Matthew A Saxonhouse; M Tariq Bhatti; William T Driebe; Bridget E Freeman; Bernard L Maria; Paul R Carney
Journal:  J Child Neurol       Date:  2002-05       Impact factor: 1.987

Review 10.  Catastrophic antiphospholipid syndrome: a clinical review.

Authors:  Ali Nayer; Luis M Ortega
Journal:  J Nephropathol       Date:  2014-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.